Indonesia

Pt Taisho Pharmaceutical Indonesia Tbk

An EMIS Company Report EMIS is a Euromoney Institutional Investor plc company USD 29.95 Industry: Pharmaceutical and Medicine Manufacturing Available in: English & Indonesian Format: PDF Download Most recent financial data: 2010 Buy full report

What’s included?

This report extracts all available information about Pt Taisho Pharmaceutical Indonesia Tbk from EMIS' database of company information. The Table of Contents on the right indicates the categories of information that will be included in your report upon purchase.

Download a sample report

Company Tear Sheet (locked content will be provided in the purchased report)

Contact Information

Legal Address
Wisma Tamara 10th Floor,Jl. Jenderal Sudirman Kav. 24
Jakarta; Jakarta; Map
Postal Code: 12920

Tel: +62-21-520-
Fax: +62-21-520-

Company Description
PT. Taisho Pharmeceutical Indonesia Tbk. (SQBI), formerly PT. Bristol-Myers Squibb Indonesia Tbk., operates in the development, registration, processing, production and selling of chemical, pharmaceutical and health care products. SQBI manufactures vitamins, analgesics, cardiovascular agents, steroids, antifungals, and antibiotics. In the production, company has tablet press machine, comil, bohle mill; water purification, boiler and generator set facilities. SQBI purchases its raw materials from PT. Mead Johnson, Bristol-Myers Squibb and Lawrence Laboratories. SQBI sells their products locally and exports to the Philippines, Malaysia, Hong Kong, Singapore, Ireland, Italy and Thailand. SQBI was listed on Indonesia Stock Exchange in 1983 under Development Board. The company was founded in 1970 and based in Jakarta, Indonesia.
NAICS Industry Classification
Main Activities: Pharmaceutical and Medicine Manufacturing
Basic Information
Total Employees:
114 (2010)
Outstanding Shares:
: ()
: ()
Financial Auditors:
()
Incorporation Date:
1970
Profile Updated:
January 07, 2018
Key Executives
President
Secretary
Board Member
Board Member
Ownership Details
Taisho Pharmaceutical Co
91%
Other
Key Financial Highlights
2017 Q3C
Net sales revenue
Total operating revenue
Operating profit (EBIT)
EBITDA
Net Profit (Loss) for the Period
Total assets 437,760,745
Total equity
Operating Profit (EBIT) Margin
Return on Sales (ROS)
Return on Equity (ROE)
Debt to Equity
Quick Ratio
Cash Ratio
Note: units in Thousands. Statement: Non-Audited, Consolidated
Source: World's Vest Base, EMIS Company Database.
Financial Performance Charts
Top Competitors

Financial Statements

Annual Statements

EMIS Credit Analytics

EMIS Benchmark Score
Enterprise ACCESS

If you need regular and ongoing access to company information, you should consider a subscription to the full EMIS service.

EMIS company profiles are part of a larger information service where that combines company, industry and country data and analysis for over 125 emerging markets on a unique information platform.

REQUEST A DEMO

To view more information, REQUEST A DEMO